Congress mandates IVF coverage in health plans, banning cost discrimination

What it does

This bill amends the Affordable Care Act to require health insurance plans to cover fertility treatment and care—including IVF, egg/sperm freezing, genetic testing of embryos, and related medications—as an essential health benefit. Plans cannot charge higher copays, deductibles, or other cost-sharing for fertility care than they do for other medical services, cannot deny coverage based on an infertility diagnosis, and must report to Congress on how they apply utilization restrictions to fertility benefits.

Why we flagged it

The bill's core function is to mandate insurance coverage of fertility treatments as an essential health benefit with parity pricing and utilization oversight. It is a consumer-protection and healthcare-access measure, not a tax provision, subsidy, or commemorative act.

What the text implies

• Insurers may respond by raising premiums across all plans to offset fertility coverage costs, potentially shifting costs to non-fertility-seeking enrollees.
• The bill does not specify who pays for the coverage expansion—whether costs are absorbed by insurers, employers, or passed to consumers via higher premiums.
• Utilization management reporting requirement creates ongoing compliance burden and potential litigation risk for insurers over what constitutes 'clinical guidelines' compliance.
• The definition of 'fertility treatment and care' is broad and delegates specificity to the Secretary of Health and Human Services, creating regulatory uncertainty until rules are finalized.

Who it affects

Ordinary people seeking fertility treatment gain access to covered care without discriminatory cost-sharing or denial based on diagnostic status. The mandate reduces out-of-pocket costs for a significant population and ensures parity with other medical benefits. The reporting requirement increases transparency and accountability in insurance practices.

Who stands to gain

• fertility clinics and reproductive medicine providers
• pharmaceutical companies (fertility medications)
• genetic testing laboratories
• health insurance plans (if they can negotiate lower reimbursement rates)

Named in the bill

Patient Protection and Affordable Care Act (ACA), Section 1302 (essential health benefits), Section 2730 (new insurance requirements), American Society for Reproductive Medicine, Secretary of Health and Human Services, Comptroller General of the US, Individual and small group health insurance markets, GNPX (Genpact, semantic affinity), GH (Guardant Health, regulatory exposure), PFE (Pfizer, regulatory exposure), DVA (DaVita, regulatory exposure), BMY (Bristol Myers Squibb, regulatory exposure)

Where it stands

1 cosponsor: 1 Democrats.

• May 19, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 19, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $90,000 in lobbying spend. A filing names 18 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Lauren Underwood, the sponsor, reported $424,700 in PAC receipts in the 2026 cycle.

• Massachusetts Medical Society — $90,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.